anti-Activin Receptor Type I (ACRV1) Antikörper

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Zusätzlich bieten wir Ihnen Activin Receptor Type I Proteine (35) und Activin Receptor Type I Kits (16) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
ACRV1 90 Q04771
ACRV1 79558 P80201
ACRV1 11477 P37172
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top anti-Activin Receptor Type I Antikörper auf antikoerper-online.de

Showing 10 out of 180 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Anbieter Lieferzeit Preis Details
Rind (Kuh) Kaninchen Unkonjugiert WB Host:  Rabbit  Target Name:  ACVR1  Sample Type:  Human Fetal Heart  Antibody Dilution:  1.0ug/ml Host:  Rabbit  Target Name:  ACVR1  Sample Type:  Human Fetal Lung  Antibody Dilution:  1.0ug/ml 100 μL Anmelden zum Anzeigen 2 bis 3 Tage
$289.00
Details
Rind (Kuh) Kaninchen Unkonjugiert IHC, WB WB Suggested Anti-ACVR1 Antibody Titration:  0.2-1 ug/ml  Positive Control:  HepG2 cell lysate Human Muscle 100 μL Anmelden zum Anzeigen 2 bis 3 Tage
$319.00
Details
Human Ziege Unkonjugiert IHC, ELISA, WB ABIN238620 (0.3µg/ml) staining of Human Umbilical Cord lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 100 μg Anmelden zum Anzeigen 6 bis 7 Tage
$429.84
Details
Human Kaninchen Unkonjugiert WB Western blot analysis of ACVR1 (arrow) using rabbit polyclonal ACVR1 Antibody (Center) (ABIN657777). 293 cell lysates (2 µg/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the ACVR1 gene. Anti-ACVR1 Antibody (Center) at 1:2000 dilution + A549 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 57 kDa Blocking/Dilution buffer: 5% NFDM/TBST. Dilution: 1:2000 400 μL Anmelden zum Anzeigen 10 bis 11 Tage
$385.00
Details
Human Kaninchen Unkonjugiert IHC (p), WB The anti-ACVR1 Pab (ABIN392240) is used in Western blot to detect ACVR1 in HeLa cell lysate (Lane 1) and mouse liver tissue lysate (Lane 2). Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. BC = breast carcinoma. HC = hepatocarcinoma 400 μL Anmelden zum Anzeigen 10 bis 11 Tage
$385.00
Details
Human Maus Unkonjugiert ELISA, FACS, WB Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng) Western blot analysis using ACVR1 mAb against human ACVR1 (AA: 21-120) recombinant protein. (Expected MW is 37.1 kDa) 0.1 mg Anmelden zum Anzeigen 8 bis 11 Tage
$577.50
Details
Human Ziege Unkonjugiert CyTOF, FACS, IHC, WB Detection of Activin RIA/ALK-2 in PC-3 Human Cell Line by Flow Cytometry. Activin RIA/ALK-2 in Human Astrocytoma. 100 μg Anmelden zum Anzeigen 8 bis 9 Tage
$435.05
Details
Human Kaninchen Unkonjugiert EIA, IHC (p), WB Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. Western blot analysis of anti-ACVR1 Pab in mouse brain tissue lysate.ACVR1(arrow) was detected using the purified Pab. 0.4 mL Anmelden zum Anzeigen 6 bis 8 Tage
$484.00
Details
Human Kaninchen Unkonjugiert EIA, IHC (p), WB Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. Western blot analysis of ACVR1 (arrow) using rabbit polyclonal ACVR1 Antibody 0.4 mL Anmelden zum Anzeigen 6 bis 8 Tage
$484.00
Details
Human Kaninchen Unkonjugiert EIA, WB Western blot analysis of anti-ACVR1 Pab in mouse brain tissue lysate. ACVR1(arrow) was detected using the purified Pab. 0.4 mL Anmelden zum Anzeigen 6 bis 8 Tage
$484.00
Details

Am meisten referenzierte anti-Activin Receptor Type I Antikörper

  1. Human Polyclonal ACRV1 Primary Antibody für CyTOF, FACS - ABIN4899715 : Fujimoto, Ohte, Shin, Yoneyama, Osawa, Miyamoto, Tsukamoto, Mizuta, Kokabu, Machiya, Okuda, Suda, Katagiri: Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. in Biochemical and biophysical research communications 2014 (PubMed)
    Show all 4 Pubmed References

  2. Human Polyclonal ACRV1 Primary Antibody für IHC (p), ELISA - ABIN543600 : Schneider-Kolsky, Manuelpillai, Waldron, Dole, Wallace: The distribution of activin and activin receptors in gestational tissues across human pregnancy and during labour. in Placenta 2002 (PubMed)
    Show all 3 Pubmed References

  3. Human Polyclonal ACRV1 Primary Antibody für IHC (p), WB - ABIN392240 : ten Dijke, Ichijo, Franzén, Schulz, Saras, Toyoshima, Heldin, Miyazono: Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. in Oncogene 1993 (PubMed)
    Show all 4 Pubmed References

  4. Human Polyclonal ACRV1 Primary Antibody für IHC (p), ELISA - ABIN544432 : Weber, Teresi, Broelsch, Frilling, Eng: A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. in The Journal of clinical endocrinology and metabolism 2006 (PubMed)
    Show all 2 Pubmed References

  5. Dog (Canine) Polyclonal ACRV1 Primary Antibody für IHC (p), ELISA - ABIN548053 : Shore, Xu, Feldman, Fenstermacher, Cho, Choi, Connor, Delai, Glaser, LeMerrer, Morhart, Rogers, Smith, Triffitt, Urtizberea, Zasloff, Brown, Kaplan: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. in Nature genetics 2006 (PubMed)

  6. Chicken Polyclonal ACRV1 Primary Antibody für IHC (p), IP - ABIN550344 : Macías-Silva, Hoodless, Tang, Buchwald, Wrana: Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. in The Journal of biological chemistry 1998 (PubMed)
    Show all 3 Pubmed References

  7. Human Polyclonal ACRV1 Primary Antibody für WB - ABIN391156 : Kan, Liu, McGuire, Berger, Awatramani, Dymecki, Kessler: Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. in Stem cells (Dayton, Ohio) 2009 (PubMed)

Weitere Antikörper gegen Activin Receptor Type I Interaktionspartner

Human Activin Receptor Type I (ACRV1) Interaktionspartner

  1. AFAP1-AS1 functions as an endogenous RNA by competitively binding to miR-384 to regulate ACVR1, thus conferring inhibitory effects on pancreatic cancer cell stemness and tumorigenicity

  2. this study characterized the ALK2 mutants R258G, G328V and F246Y, which were identified in patients with severe fibrodysplasia ossificans progressiva, diffuse intrinsic pontine glioma and unusual hereditary skeletal dysplasia, respectively.

  3. Identification of small molecule inhibitors of ALK2: a virtual screening, density functional theory, and molecular dynamics simulations study.

  4. Results showed that ACVR1 was a direct target of miR-384 and was involved in the inhibitory effects of miR-384 on breast cancer progression. Furthermore, the study indicated that ACVR1 activated the Wnt/beta-catenin signaling pathway in breast cancer.

  5. Study emphasizes about the role of ACVR1 which encoding a receptor for BMP proteins in fibrodysplasia ossificans progressiva (FOP). Most FOP patients carry the recurrent R206H substitution in the GS domain, whereas a few other mutations are responsible for limited cases. Mutations cause a dysregulation of the downstream BMP-dependent pathway making mutated ACVR1 responsive to a non-canonical ligand, Activin A. [review]

  6. The role of an ALK2 mutation (R258S) in IRIDA development in a patient also bearing compound heterozygous mutations in TMPRSS6 was demonstrated by reconstructing in vitro the proband's genotype, expressing mutants TMPRSS6 and ACVR1 in the presence of hemojuvelin and assessing hepcidin activation. ALK2(R258S) maintained high hepcidin expression in the presence of MT2(I212T).

  7. activation of AMPK upregulated Smad6 and Smurf1 and thereby enhanced their interactions, resulting in its proteosome-dependent degradation of ALK2.

  8. the Fibrodysplasia Ossificans Progressiva mutation ACVR1(R206H) is more sensitive to a number of natural ligands.

  9. both bone morphogenetic protein 2 (BMP2) and BMP6 are proangiogenic in vitro and ex vivo and that the BMP type I receptors, activin receptor-like kinase 3 (ALK3) and ALK2, play crucial and distinct roles in this process.

  10. Fibrodysplasia ossificans progressiva (FOP) syndrome is caused by mutation of the gene ACVR1. Developed is a simplified one-step procedure by simultaneously introducing reprogramming and gene-editing components into human fibroblasts derived from patient with FOP. The one-step-mediated ALK2 gene-corrected induced pluripotent stem cells restored global gene expression pattern.

  11. The ACVR1 R206H mutation may not directly increase the formation of mature chondrogenic or osteogenic cells.

  12. Authors demonstrated that the BMP type I receptor ALK-2 (encoded by the ACVR1 gene) has crucial roles in apoptosis induction of patient-derived glioma-initiating cells (GICs), TGS-01 and TGS-04.

  13. Data suggest BMP9/GDF2 and BMP10 synergize with TNFA to increase monocyte recruitment to vascular endothelial cells; process appears to be mediated mainly via ALK2/ACVR1 (which exhibits protein kinase activity). These studies used in vitro flow monocyte adhesion assay. (BMP9 = growth differentiation factor 2; BMP10 = bone morphogenetic protein 10; TNFA = tumor necrosis factor alpha; ALK2/ACVR1 = activin A receptor type 1)

  14. The effects of ACVR1/ALK2 mutations causing fibrodysplasia ossificans progressiva are extended to the central nervous system. Brainstem hamartomatous lesions and dysmorphisms, variably associated with dentate nucleus and basal ganglia signal abnormalities and/or calcifications, may represent useful disease hallmarks.

  15. Low ALK2 expression is associated with invasiveness of breast cancer.

  16. Further investigation on clinical ESCC samples and non-tumorous adjacent tissue found that tumors with triple-positive BMP6, ALK2 and BMPRII had deeper growth than tumors with only BMP6 expression

  17. The clinical manifestations, the disease course, and the molecular findings of involvement of ACVR1 gene in this family are suggestive of "FOP variant" or an unusual ACVR1-related skeletal dysplasia

  18. Activin-A is increased in the airway of asthmatics and peaks during asthma exacerbations.Activin-A signalling pathways are dysregulated in severe asthma.

  19. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

  20. The higher PE activin A concentrations resulted in abnormal endothelial functions, which may contribute to the systemic maternal vascular endothelial cell dysfunction observed in the disorder.

Mouse (Murine) Activin Receptor Type I (ACRV1) Interaktionspartner

  1. increased bone morphogenetic proteins signaling in Acvr1(R206H/+) cells alters the tissue microenvironment and results in misinterpretation of the tissue microenvironment through altered sensitivity to mechanical stimuli that lowers the threshold for commitment to chondro/osteogenic lineages.

  2. This study demonstrates for the first time the physiological roles of ACVR1 during dentinogenesis.

  3. Systemic activation of Activin A signaling causes chronic kidney disease-mineral bone disorder. (Review)

  4. findings demonstrate that hair follicle specific ALK2 is intricately involved in maintenance of the stem cell niche and wound healing

  5. targeted expression to fibro/adipogenic progenitors recapitulates the full spectrum of heterotopic ossification observed in fibrodysplasia ossificans progressiva patients

  6. NODAL/Activin signaling induces dramatic chromatin landscape changes, and a dynamic transcriptional network regulated by SMAD2, acting via multiple mechanisms.

  7. Acute tacrolimus treatment transiently increases hepcidin in wild-type mice. FKBP12 preferentially targets the BMP receptor ALK2. ALK2 mutants defective in binding FKBP12 increase hepcidin expression in a ligand-independent manner, through BMP-SMAD signaling.

  8. The authors demonstrated that ubiquitin-specific protease (USP) 4 strongly induces activin/BMP signaling by removing the inhibitory monoubiquitination from SMAD4.

  9. Enhanced SMAD-dependent BMP signaling through constitutively active ACVR1 in palatal epithelium causes submucous cleft palate in mice, via medial-edge-epithelium persistence presumably due to the up regulation of DeltaNp63 andresultingreductionofcaspase-3 activation. 2.

  10. BMP signaling mediated by coordination of ALK2/ACVR1, ALK3/BMPR1A, and BMPR2 is an essential proangiogenic cue for retinal vessels.

  11. This study showed that Gja1 may act downstream of cAMP-PKA signal to mediate the effects of Acvr1 on the differentiation of uterine stromal cells through targeting Hand2.

  12. Results showed activin-C and follistatin are differentially expressed during prostate development and suggested that the antagonistic property of follistatin is secondary to the action of activin-C. Study provides evidence to support a role of activin-C in prostate development and provides new insights in the spatiotemporal localization of activins and their antagonists during mouse prostate development.

  13. BMPR1B plays distinct roles from BMPR1A and ACVR1 in maintaining bone mass and transducing BMP signaling

  14. Suggest that BMP signaling upregulates the calcineurin/nuclear factor of activated T cell pathway via BMP type I receptor ALK2, contributing to cardiac hypertrophy and fibrosis.

  15. results suggest that ACVR1(R206H) causes FOP by gaining responsiveness to the normally antagonistic ligand activin A, demonstrating that this ligand is necessary and sufficient for driving HO in a genetically accurate model of FOP

  16. The findings suggest that the mutant ALK2 related to Fibrodysplasia ossificans progressiva is enhanced by bone morphogenetic protein type II receptors via the T203-regulated phosphorylation of ALK2.

  17. ACVR1 is required for chondrocyte proliferation and differentiation, particularly in craniofacial and axial elements, but exerts coordinated functions with both BMPR1A and BMPR1B throughout the developing endochondral skeleton

  18. expression of constitutively active ALK2 receptor results in significantly increased ASC osteogenic differentiation.

  19. SP-10 is a useful marker for staging the cycle of the seminiferous epithelium. The anti-SP-10 antibody works well in different fixatives, on paraffin-embedded as well as cryosections

  20. Data indicate that activin A receptor type 1 (Alk2) is a direct regulator of cartilage formation and mediates chondrogenic commitment of progenitor cells.

Horse (Equine) Activin Receptor Type I (ACRV1) Interaktionspartner

  1. Data suggest that ACVR1 mRNA and protein are present in granulosa cells of ovarian follicles at mid-estrous and pre-ovulatory stages; ACVR1 mRNA and protein are also present in exosomes isolated from mid-estrous and preovulatory follicles.

Activin Receptor Type I (ACRV1) Antigen-Profil

Protein Überblick

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I ( I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling\; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type I receptor which signals a particular transcriptional response in concert with activin type II receptors. Mutations in this gene are associated with fibrodysplasia ossificans progressive.

Genbezeichner und Symbole assoziert mit ACRV1

  • activin A receptor type 1 (ACVR1) Antikörper
  • activin A receptor type 1 (Acvr1) Antikörper
  • activin A receptor, type 1 (Acvr1) Antikörper
  • activin A receptor type 1 S homeolog (acvr1.S) Antikörper
  • ActR-I Antikörper
  • ActR-IA Antikörper
  • actri Antikörper
  • ActRIA Antikörper
  • Acvr Antikörper
  • acvr1 Antikörper
  • acvr1-a Antikörper
  • acvr1-b Antikörper
  • acvr1a Antikörper
  • acvrlk2 Antikörper
  • alk-2 Antikörper
  • alk2 Antikörper
  • alk8 Antikörper
  • D330013D15Rik Antikörper
  • fop Antikörper
  • sax Antikörper
  • skr1 Antikörper
  • Tsk7L Antikörper
  • tsri Antikörper
  • xALK-2 Antikörper

Bezeichner auf Proteinebene für ACRV1

TGF-B superfamily receptor type I , activin A receptor, type II-like kinase 2 , activin receptor type I , activin receptor type-1 , activin receptor-like kinase 2 , hydroxyalkyl-protein kinase , serine/threonine-protein kinase receptor R1 , ACTR-I , SKR1 , TSR-I , activin A receptor, type 1 , activin type I receptor , type I TGF B receptor , activin A receptor, type I , activin receptor type IA , TSK-7L , activin A receptor type 1 S homeolog , activin A receptor type I S homeolog , activin receptor like kinase-2

GENE ID SPEZIES
90 Homo sapiens
79558 Rattus norvegicus
338068 Bos taurus
395246 Gallus gallus
443161 Ovis aries
11477 Mus musculus
478757 Canis lupus familiaris
100724428 Cavia porcellus
399083 Xenopus laevis
100050899 Equus caballus
697935 Macaca mulatta
Ausgewählte Anbieter für anti-Activin Receptor Type I (ACRV1) Antikörper
Haben Sie etwas anderes gesucht?